FDA raises cardio concerns on Forest's new COPD drug

Forest Laboratories ($FRX) and Almirall got a thumbs up from the FDA for their efficacy data on a COPD drug candidate. But regulators want an upcoming panel review to closely explore cardio risks linked with the entire drug class it belongs to. One big issue is whether the companies designed large enough trials to accurately gauge the cardio risk. Story

Add new comment

Images
More information
  • Files must be less than 2 MB.
  • Allowed file types: png gif jpg jpeg.
Documents
More information
  • Files must be less than 2 MB.
  • Allowed file types: zip rar.